Skip to main content

Context Therapeutics Inc.

corporate_fare Company Profile

Context Therapeutics Inc.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CNTX - Latest Insights

CNTX
Apr 28, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on 100 Million Share Increase, Enabling Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Apr 17, 2026, 4:29 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Context Therapeutics Seeks Shareholder Approval to Double Authorized Common Stock
Sentiment: Negative
View Wiseek Article
CNTX
Apr 02, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Apr 02, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Partial Response Reported for Context's CTIM-76, Key Milestones Ahead; Cash Runway into Mid-2027
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Partial Response in CTIM-76 Phase 1a Trial, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
CNTX
Mar 23, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Context Therapeutics Reports Increased Losses, $75M ATM Program, and Over 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
CNTX
Mar 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Court Approves Governance Changes, Eliminating Staggered Board and 'For Cause' Director Removal
Sentiment: Positive
View Wiseek Article
CNTX
Feb 27, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics to Adopt Annual Director Elections, Resolving Shareholder Lawsuit
Sentiment: Positive
View Wiseek Article
CNTX
Jan 08, 2026, 7:43 AM EST
Filing Type: 8-K
Importance Score:
8
Context Therapeutics Reports Positive Interim Phase 1a Data for CTIM-76 and Extends Cash Runway
Sentiment: Positive
View Wiseek Article